Abbott Laboratories is expected to report second-quarter revenue of $12.52 billion and adjusted EPS of $1.28, with shares currently trading near $89.88 against an average analyst price target of $118.42. The primary focus for investors is the integration of the $23 billion Exact Sciences acquisition and its contribution to the newly established oncology diagnostics vertical.
Market participants are closely monitoring the $0.20 per-share dilution impact on full-year earnings and the potential for a rebound in the nutrition segment following recent softness. Despite recent price volatility, the medical device division continues to exhibit strength, particularly within the FreeStyle Libre platform and structural heart portfolios.